A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (NCT06356311)
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
🩺 Plain-English Summary (8th-Grade Level)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center ( Site 0119) — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (168 Sites)
Showing the first 25 of 168 sites.
- Banner MD Anderson Cancer Center ( Site 0119) — Gilbert, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 0140) — Los Angeles, California
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129) — Orlando, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108) — Marietta, Georgia
- University of Chicago Medical Center ( Site 0120) — Chicago, Illinois
- University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124) — Lexington, Kentucky
- The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113) — Louisville, Kentucky
- Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105) — Louisville, Kentucky
- Henry Ford Hospital ( Site 0107) — Detroit, Michigan
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138) — Fargo, North Dakota
- Oregon Health and Science University ( Site 0104) — Portland, Oregon
- UPMC Hillman Cancer Center ( Site 0126) — Pittsburgh, Pennsylvania
- MUSC Hollings Cancer Center-Hematology Oncology ( Site 0122) — Charleston, South Carolina
- Sanford Cancer Center ( Site 0136) — Sioux Falls, South Dakota
- The West Clinic, PLLC dba West Cancer Center ( Site 0110) — Germantown, Tennessee
- Inova Schar Cancer ( Site 0106) — Fairfax, Virginia
- Fred Hutchinson Cancer Center ( Site 0111) — Seattle, Washington
- Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003) — Anderlecht, Bruxelles-Capitale, Region de
- Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001) — Brussels, Bruxelles-Capitale, Region de
- UZ Leuven-Digestive Oncology ( Site 1000) — Leuven, Vlaams-Brabant
- AZ Delta vzw ( Site 1002) — Roeselare, West-Vlaanderen
- Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405) — Fortaleza, Ceará
- Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406) — Natal, Rio Grande do Norte
- Hospital de Caridade de Ijuí ( Site 0412) — Ijuí, Rio Grande do Sul
- Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400) — Porto Alegre, Rio Grande do Sul
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastroesophageal Cancer
- Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer — Tampa, Florida
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer — Baltimore, Maryland
- Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer — Tampa, Florida
Explore by condition: All Gastroesophageal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.